Skip to content

Total debt at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$82.17M-6.5%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Eli Lilly logo
Eli LillyLLY
Johnson & Johnson logo
Johnson & JohnsonJNJ
Amgen logo
AmgenAMGN
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$4.36B+533%
Enterprise value$4.32B+690%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $1.81M.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s total debt?
Oruka Therapeutics, Inc. (ORKA) reported total debt of $1.81M in Q1 2026.
How has Oruka Therapeutics, Inc.'s total debt changed year-over-year?
Oruka Therapeutics, Inc.'s total debt increased by 90.8% year-over-year, from $947K to $1.81M.
What is the long-term trend for Oruka Therapeutics, Inc.'s total debt?
Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s total debt has grown at a 33.8% compound annual growth rate (CAGR), from $450K to $1.93M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.